Delaware Chapter of the American College of CardiologyOur purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments. |
|
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- JACC Featured Science: ECG-AI For HF Risk; ANSWER-HF; NEO-MINDSET; MANIFEST-USFeatured science studies simultaneously published in JACC and presented at AHA 2025 looked at artificial intelligence applied to an electrocardiogram (ECG-AI) for heart failure (HF) risk, treatment of Chagas disease, early aspirin withdrawal in STEMI and non-ST-segment elevation acute coronary syndrome (NSTE-ACS), and safety of the pentaspline pulsed-field ablation (PFA) catheter.
- Secondary Cardiovascular Prevention For Survivors of Childhood CancerApproximately half a million people in the United States are survivors of cancer diagnosed in childhood or adolescence. Over 50% of pediatric cancer patients have been treated with curative, but cardiotoxic, anthracycline-based therapies.
- ACC CardiaCast: Innovation in Action: Leveraging Wearables in Cardiovascular CareIn this episode, ACC Chief Innovation Officer Dr. Ami Bhatt and Dr. Sanket Dhruva explore how wearables are shaping the future of personalized care.
- Research Suggests Long-Term Melatonin Use For Insomnia Increases HF RiskLong-term melatonin use for insomnia was associated with a higher hazard of heart failure (HF), an increase in HF hospitalizations and a doubling of all-cause mortality over five years, according to a large, multinational cohort study presented at AHA 2025.
- FOOD-HF: Can Food-as-Medicine Work After Discharge? Exploring Feasibility and FitFood supplementation for patients following a heart failure (HF)-related hospitalization was both feasible and acceptable and associated with clinically meaningful improvement in quality of life compared with usual care, based on findings from the FOOD-HF trial presented at AHA 2025.



